Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $285.98 (market cap $39.89B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.92. The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | SJNK | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Sector/Thematic |
52-Week High | $491.22 | $25.63 |
52-Week Low | $278.09 | $24.75 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
SJNK, the SPDR Bloomberg Short Term High Yield Bond ETF, trades at $24.91, down slightly by 0.08% over 24 hours. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF maintains a consistent dividend payout schedule, with recent distributions of $0.14 and $0.15 per share. Recent news highlights institutional interest, with Berkshire Money Management increasing its stake by 3.0% as of the latest SEC filing in April 2026.
The outlook for SJNK is clouded by bearish technicals and cautious analyst sentiment, with some sources rating it a SELL due to exhausted tailwinds from falling yields. Key risks include high sensitivity to interest rate changes and credit spread volatility. However, its monthly dividend history since 2012 and institutional accumulation may appeal to income-focused investors willing to navigate short-term market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
